For patients with symptomatic and severe tricuspid regurgitation (TR), tricuspid transcatheter edge-to-edge repair (T-TEER) yields significant improvements in primary end points, according to a study ...

Transcatheter tricuspid-valve replacement is superior to medical therapy alone for patients with severe tricuspid ...

The benefit was confined to symptoms, but in a very sick population with few options, that’s important, say researchers.

For patients with symptomatic and severe or greater tricuspid regurgitation (TR), transcatheter tricuspid valve replacement ...

Edwards Lifesciences (NYSE:EW) today announced data highlighting the superiority of its Evoque system compared to medical ...

New analyses bolster the case for tricuspid TEER and reassure on outcomes in patients with implanted electronic devices.

Amir Danino, CEO of Innoventric, stated: “Our mission is to revolutionize tricuspid regurgitation care with minimally invasive therapies that significantly improve patient outcomes. The strong backing ...

Sandra Lesenfants, senior vice president of Abbott’s Structural Heart business, shares an update on MitraClip, TriClip, and ...

TRISCEND II is a randomized controlled pivotal trial designed to study the groundbreaking EVOQUE transcatheter tricuspid valve replacement (TTVR) system with optimal medical therapy (OMT) compared to ...

In this cohort study, the Kansas City Cardiomyopathy Questionnaire (KCCQ) had strong psychometric properties in patients with ...

Transcatheter tricuspid-valve replacement is superior to medical therapy alone for patients with severe tricuspid regurgitation, according to a study published online Oct. 30 in the New England ...

Severe tricuspid regurgitation is associated with disabling symptoms and an increased risk of death. Data regarding outcomes after percutaneous transcatheter tricuspid-valve replacement are needed.